Researchers at Stanford Medicine have developed a groundbreaking universal vaccine candidate that, based on studies conducted in mice, demonstrates protection against a diverse array of respiratory viruses, bacteria, and allergens. Unlike existing vaccines, this novel intranasal vaccine offers extended protection in the lungs for several months, indicating a significant advancement in immunization strategies.
The team, led by Bali Pulendran, PhD, who is the director of the Institute for Immunity, Transplantation and Infection, and a professor at Stanford University, has integrated both branches of the immune system—innate and adaptive—to create a feedback loop that sustains a broad immune response. Vaccinated mice showed resilience against SARS-CoV-2, various coronaviruses, as well as common hospital-acquired infections like Staphylococcus aureus and Acinetobacter baumannii. They were also protected from allergic reactions related to house dust mites.
Pulendran highlighted the potential transformative impact of this vaccine, stating that if proven safe and effective in humans, it could simplify the seasonal vaccination process and enhance preparedness for emerging respiratory threats. He noted, “The reported work is preclinical, and our goal is to translate our research carefully and responsibly.”
Addressing an Urgent Need for Broader Protection
The research, published in the journal Science, indicates an urgent requirement for a broadly protective vaccine that can effectively combat rapidly mutating pathogens. Traditional vaccines target specific antigens, which limits their effectiveness against diverse respiratory threats. “It’s becoming increasingly clear that many pathogens are able to quickly mutate,” Pulendran stated, emphasizing the limitations of existing vaccination strategies.
The innovative approach of this newly developed vaccine does not mimic any part of a pathogen. Instead, it replicates the signals that immune cells utilize to communicate during infections. This paradigm shift focuses on recreating key immune communication signals in the lungs, maintaining a heightened protective state while engaging adaptive immunity for long-term effects.
Pulendran explained that this method has not been mainstream due to historical prioritization of antigen specificity in vaccine development. Achieving broad innate protection without causing systemic inflammation has also posed challenges.
A New Framework for Vaccine Development
Historically, attempts at a universal vaccine have sought to induce immunity across entire families of viruses. The notion of a vaccine capable of counteracting diverse pathogens was often considered implausible. “We were interested in this idea because it sounded a bit outrageous,” Pulendran remarked.
The innate immune system, which provides immediate defense against pathogens, offers a form of universal protection. While it typically lasts only a few days, the researchers discovered that a sustained innate response could be achieved. In a previous study, they found that T cells, recruited as part of the adaptive response, send signals to keep the innate immune cells active for months, providing extended protection against infections.
The new vaccine, designated GLA-3M-052-LS+OVA, incorporates T cell signals that stimulate innate immune cells in the lungs. It also contains ovalbumin (OVA), a harmless antigen that helps maintain the innate response for weeks. In trials, vaccinated mice demonstrated significant resistance against respiratory viruses, suffering less weight loss and showing minimal viral presence in their lungs.
The researchers also tested the vaccine against bacterial respiratory infections, confirming that vaccinated mice were protected from both Staphylococcus aureus and Acinetobacter baumannii for approximately three months. Moreover, the vaccine demonstrated effectiveness in preventing allergic reactions to house dust mites, indicating its broad applicability.
If successful in human trials, this vaccine could replace multiple annual injections for seasonal respiratory infections and be available as a countermeasure for pandemic viruses. Pulendran anticipates that two doses of a nasal spray could provide adequate protection for humans.
The research team is now evaluating various vaccine candidates with different compositions and dosages in preparation for future human trials. The next steps involve formal toxicology studies to assess safety and immune response, as well as securing funding to support these initiatives.
In an optimistic scenario, Pulendran estimates that a universal respiratory vaccine could be available within five to seven years. This advancement could significantly alter the landscape of respiratory illness prevention, providing broad protection from a range of pathogens and simplifying seasonal vaccinations. “Imagine getting a nasal spray that protects you from all respiratory viruses, including COVID-19 and influenza,” he stated, underlining the transformative potential of this research.
